To the uninitiated, the ‘Life Risk market’ is an umbrella term those in investment circles use to describe the transfer of mortality or longevity risk from the primary market to the capital markets. It manifests itself as two sides of the same coin; ‘mortality risk’ refers to the risk of loss arising from a population that experiences a shorter than expected lifespan whereas ‘longevity risk’ considers the opposite.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Post a comment
Related Posts
New Report Suggests Life Settlement Market Poised for Long-Term Expansion
Structural tailwinds provide positive outlook but complexities still need to be managed.
The Structural Decision for Setting Up a Life Settlement Vehicle in Ireland
Two different structuring options provide flexibility for life settlement investors.
Litigation Update: U.S. Bank National Association v. Pacific Life Insurance Company
A recent decision by Judge Thomas J. Lo of the Superior Court of California, Orange…
Is Dementia the Next Big Longevity Event?
For many countries with ageing populations, dementia presents major challenges. Richard Marshall, Senior Director and…
